公开(公告)号：US20200062730A1

公开(公告)日：2020-02-27

申请号：US16609805

申请日：2018-05-11

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Jong Yeon HWANG ,  Jae Du HA ,  Sung Yun CHO ,  Pil Ho KIM ,  Chang Soo YUN ,  Chi Hoon PARK ,  Chong Ock LEE ,  Sang Un CHOI ,  Joo Youn LEE ,  Sunjoo AHN

IPC: C07D401/04 ,  A61P35/00 ,  C07D401/14

Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.

公开(公告)号：US20180104242A1

公开(公告)日：2018-04-19

申请号：US15567224

申请日：2015-12-30

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Jong Yeon HWANG ,  Hyoung Rae KIM ,  Jae Du HA ,  Sung Yun CHO ,  Hee Jung JUNG ,  Pilho KIM ,  Chang Soo YUN ,  Chong Ock LEE ,  Chi Hoon PARK ,  Chong Hak CHAE ,  Sunjoo AHN

IPC: A61K31/506 ,  A61P35/00 ,  C07D239/48 ,  C07D239/30 ,  C07C13/48 ,  C07B43/04

CPC classification number: A61K31/506 ,  A23L33/10 ,  A61P35/00 ,  C07B43/04 ,  C07B2200/07 ,  C07C13/48 ,  C07D239/30 ,  C07D239/48

Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

公开(公告)号：US20240018123A1

公开(公告)日：2024-01-18

申请号：US18017997

申请日：2021-07-28

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  UBIX THERAPEUTICS, INC.

Inventor： Jong Yeon HWANG ,  Jae Du HA ,  Hyun Jin KIM ,  Sung Yun CHO ,  Pilho KIM ,  Chong Ock LEE ,  Jeong Hoon KIM ,  Byoung Chul PARK ,  Sung Goo PARK ,  Sunhong KIM ,  Yuri CHOI ,  Yaejin WOO ,  Song Hee LEE ,  Je Ho RYU ,  Jungmin AHN ,  Ji Youn PARK ,  Onnuri BAE ,  Hanwool KIM

IPC: C07D401/14 ,  C07D295/155 ,  C07D211/26

CPC classification number: C07D401/14 ,  C07D211/26 ,  C07D295/155

Abstract: The present disclosure provides a compound of a chemical structure having the ability of inhibiting or disintegrating an androgen receptor (AR), or a pharmaceutically acceptable salt of the compound. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of AR-related diseases. The present disclosure also provides a method for treating or preventing AR-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present disclosure, a salt thereof, or a composition comprising same.

公开(公告)号：US20170145007A1

公开(公告)日：2017-05-25

申请号：US15319151

申请日：2015-05-21

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Chang Soo YUN ,  Hyoung Rae KIM ,  Sung Yun CHO ,  Hee Jung JUNG ,  Kwangho LEE ,  Chong Hak CHAE ,  Chong Ock LEE ,  Chi Hoon PARK ,  Pilho KIM ,  Jong Yeon HWANG ,  Jae DU HA ,  Sun Joo AHN

IPC: C07D471/04 ,  C07D405/14 ,  C07D401/14 ,  C07D403/12 ,  C07D401/12

CPC classification number: C07D471/04 ,  A61K31/506 ,  C07D209/04 ,  C07D239/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14

Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.

公开(公告)号：US20150152069A1

公开(公告)日：2015-06-04

申请号：US14617079

申请日：2015-02-09

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Kwangho LEE ,  Hyoung Rae KIM ,  Chi Hoon PARK ,  Chong Ock LEE ,  Jong Kook LEE ,  Hee Jung JUNG ,  Sung Yun CHO ,  Chong Hak CHAE ,  Sang Un CHOI ,  Jae Du HA

IPC: C07D239/48

CPC classification number: C07D239/48 ,  A61K31/506 ,  C07D403/12 ,  C07D403/14

Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.

Abstract translation: 本文公开了新的N 2，N 4 - 双（4-（哌嗪-1-基）苯基）嘧啶-2,4-二胺衍生物或其药学上可接受的盐和用于预防或治疗含有其的癌症的药物组合物 作为活性成分。 本发明的化合物对于间变性淋巴瘤激酶（ALK）和活化的cdc42相关激酶（ACK1）的活性具有优异的抑制作用，因此可以改善对具有间变性淋巴瘤激酶融合蛋白的癌细胞的治疗效果，例如 EML4-ALK和NPM-ALK，并且还有效地预防癌症的复发因此可用作用于预防和治疗癌症的药物组合物。